# Trial of PCSK9 Inhibition in Patients with Acute Stroke and Symptomatic Intracranial Atherosclerosis

> **NCT05001984** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Chang Gung Memorial Hospital** · enrollment: 60 (actual)

## Conditions studied

- Intracranial Atherosclerosis
- Acute Ischemic Stroke
- ICAS - Intracranial Atherosclerosis

## Interventions

- **DRUG:** Alirocumab

## Key facts

- **NCT ID:** NCT05001984
- **Lead sponsor:** Chang Gung Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-08-01
- **Primary completion:** 2025-04-15
- **Final completion:** 2025-04-15
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05001984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05001984, "Trial of PCSK9 Inhibition in Patients with Acute Stroke and Symptomatic Intracranial Atherosclerosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05001984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*